Arterial stiffness is an independent predictor of cardiovascular events in a hypertensive population. Serum levels of matrix metalloproteinase (MMP)-9 are associated with arterial stiffness and predict cardiovascular risk. We investigated the role of MMP-9 polymorphism À1562C4T on blood pressure (BP) and arterial stiffness in a newly diagnosed hypertensive population. Untreated hypertensive patients (n ¼ 215, mean age 46713 years) were studied. Supine BP, carotid-femoral pulse wave velocity (PWV) and augmentation index were assessed. Serum biochemistry and plasma MMP-9 concentrations were measured and genotyping performed following extraction of genomic DNA. BP, aortic PWV and serum MMP-9 levels were significantly higher in T-allele carriers of the À1562C4T polymorphism with a significant gene-dose effect (Po0.0001). In a stepwise regression model adjusting for known or likely determinants, the 1562C4T polymorphism emerged as an independent predictor of systolic BP (R 2 ¼ 0.25, Po0.0001), diastolic BP (R 2 ¼ 0.16, Po0.0001) and PWV (R 2 ¼ 0.47,Po0.0001). This is the first study to show the effect of MMP-9 polymorphism on BP and aortic stiffness in a hypertensive population. These results suggest that hypertensive patients carrying the T allele may be at increased risk of cardiovascular events.
Introduction
Essential hypertension is the most common cardiovascular disease with a worldwide prevalence of some 27% 1 and is a major risk factor for coronary artery disease (CAD) and stroke. Arterial stiffness plays an important role in the pathophysiology of hypertension. When measured as pulse wave velocity (PWV), it has been shown to be a marker of cardiovascular risk in the general population 2 and an independent prognosticator of cardiovascular events in hypertension. [3] [4] [5] Both blood pressure (BP) and arterial stiffness are a result of a complex interplay between haemodynamic forces modulated by circulating hormones and neural stimuli on one hand and vascular inflammation and structural alternations on the other. Matrix metalloproteinases (MMPs), family of more than 20 zinc-containing enzymes with proteolytic activity against extracellular matrix components such as elastin, proteoglycans and collagen, 6 play an essential role in physiological vascular remodelling. However, with excessive MMP expression and activity, inappropriate cardiovascular remodelling may occur resulting in arteriosclerosis, aneurysm formation and restenosis. 7, 8 MMP-9 (gelatinase B, 92-kDa type IV collagenase) is an important member of this family and is capable of degrading gelatine, fragments of collagen degraded by collagenase and type IV collagen, which forms part of the basement membrane. 9 Circulating MMP-9 levels are increased in hypertension, 10 in type II diabetic patients with CAD 11 and are associated with premature coronary arteriosclerosis. 7 Recently, plasma MMP-9 levels were shown to predict cardiovascular mortality in patients with CAD 12 and were associated with aortic stiffness. 13 Zhang et al. 9 described a functional À1562C/T polymorphism in the promoter region of MMP-9 characterized by a single-nucleotide change from cytosine to thymidine 1562-bp upstream from the start of transcription (C/T). This polymorphism is related to the presence and severity of arteriosclerosis 14 and large vessel stiffening in patients with CAD 15 and in healthy subjects. 16 Whether this particular genetic variant in the MMP-9 gene modulates BP and arterial stiffness in a hypertensive population is not known.
We hypothesized that the MMP-9 À1562C4T polymorphism may play an independent role in modulating BP, arterial stiffness and plasma MMP-9 levels in a population of never-treated patients with essential hypertension.
Methods

Patient population
We studied 215 never-treated Caucasian healthy hypertensive subjects with diagnosis of hypertension based on three outpatient measures of BP greater than 140/90 mm Hg and confirmed by daytime ambulatory BP 4135/85 mm Hg. The mean 7s.d. age was 46713 years and 108 were males. Patients with history, clinical or electrocardiographic evidence of CAD, peripheral vascular disease, cerebrovascular disease, valvular disorders, rhythm disturbances and signs and symptoms of congestive heart failure were excluded. The patients gave informed consent; the study had institutional ethics committee permission and the procedures followed were in accordance with the principles of the Declaration of Helsinki.
Study protocol
Height and weight were recorded and body mass index (BMI) calculated. The patients were studied in a quiet room and had abstained from smoking, alcohol or caffeinated containing beverages in the 12 h before the study. The haemodynamic measurements were performed after a supine rest of 15 min.
BP measurement BP was measured in the right arm using an automated oscillometric device (Omron Model HEM 705-CP, Omron Corporation, Tokyo, Japan). Three BP readings were taken at 1 min intervals and the mean used for data analysis. Peripheral pulse pressure was calculated as the difference between systolic and diastolic BP.
Assessment of arterial stiffness and wave reflection Carotid-femoral PWV was measured on the right side in the supine position using the automatic device (Complior, Artech Medical, France) as described previously. 17 Radial pressure waveforms were recorded by applanation tonometry to construct a corresponding aortic pressure waveform using a validated generalized transfer function (SphygmoCor, Version 8.0, AtCor Medical, Australia). The aortic pressure waveform was used to calculate the augmentation index (AIx) as the difference in height between the first and second aortic systolic peaks expressed as a percentage of aortic pulse pressure. 17 Laboratory methods Blood samples were drawn and the serum separated and stored at À801C. Fasting total cholesterol, triglycerides, high-density lipoprotein cholesterol and plasma glucose were measured using standard methods. Plasma MMP-9 concentrations were determined using a commercially available ELISA assay (Quantikine; R&D Systems, Inc., Abingdon, UK) according to the manufacturers' instructions in 80 subjects. The optical density of individual wells was determined with an automated microplate reader (BioTek Instruments Inc., Winooski, VT, USA). The intraassay coefficient of variation ranged between 2 and 2.9% and the inter-assay coefficient of variation ranged between 6.9 and 7.9%. The minimum detection limit of the MMP-9 assay was 0.156 ng/ml.
Genetic analysis
Genomic DNA was extracted from the venous blood using standard methods. Patients were genotyped for the MMP-9 À1562 C/T polymorphism using polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP). The MMP-9 promoter polymorphism À1562C4T was amplified from 100 ng of genomic DNA using the forward (5 0 -GCCTGGCACATAGTAGGCCC-3 0 ) and reverse (5 0 -CTTCCTAGCCAGCCGGCATC-3 0 ) oligonucleotide primers. PCR conditions included predenaturation at 951C for 15 min followed by 30 cycles of denaturation at 941C for 30 s, annealing at 651C for 1 min 30 s, extension at 721C for 1.5 min and a final extension at 721C for 10 min. The amplified PCR product (435 bp) was then digested with 10 U of the restriction enzyme BbU overnight (Promega, Madison, WI, USA) and the product run on a 2% agarose gel stained with ethidium bromide. CC homozygotes showed a single band at 435 bp; CT heterozygotes showed bands of 435, 247 and 188 bp while TT homozygotes showed band sizes of 247 and 188 bp. Successful genotyping of the MMP-9 C/T polymorphism was achieved for all 215 cases.
Statistical analysis
Data were analysed using JMP version 5.0 (SAS. for Windows, Cary, NC, USA). Results are expressed as mean7s.d. or 95% confidence intervals for continuous variables and percentages for categorical data, Po0.05 considered significant. Difference between continuous variables was analysed using one-way analysis of variance and categorical variables with w 2 testing. Logarithmic transformations were performed for variables that were significantly skewed.
Stepwise multiple regression analysis was performed to analyse the relationship between the MMP-9 À1562C4T polymorphism, BP and arterial stiffness adjusting for known or likely determinants of these variables in our patient population.
Results
The demographic and clinical characteristics of the patient population according to the MMP-9 À1562C4T genotype are given in Table 1 . The respective frequen-MMP-9 gene and arterial stiffness in hypertension S Zhou et al cies of the three genotypes were CC homozygotes 68%, CT heterozygote 29% and TT homozygotes 3%. Allele frequencies were 82.6 and 17.4% for the C and T alleles, respectively, and not significantly different from Hardy-Weinberg equilibrium.
There was no significant difference in age, gender, smoking status, BMI or biochemical profile between the three genotypes ( Table 1) .
Association between MMP-9 À1562C4T polymorphism and BP BP was significantly higher in the carriers of the T allele (TT homozygotes and CT heterozygotes) compared with the CC homozygotes. The À1562C4T polymorphism had a dose-dependent effect on systolic (Po0.01), diastolic (Po0.05) and mean arterial pressure (Po0.01) (Figure 1 ) with a difference of almost 16 mm Hg systolic and 8 mm Hg diastolic between the CC and TT homozygotes. To assess the relationship between BP and the À1562C4T polymorphism, we constructed stepwise regression models with known or likely confounders of BP ( Table 2 ). As expected, age was the major determinant of systolic BP followed by the À1562C4T polymorphism in addition to triglycerides, BMI and heart rate. The À1562C4T polymorphism was also an independent determinant of diastolic BP but quantitatively of lesser significance than for systolic BP (Table 2) .
MMP-9 À1562C4T polymorphism and arterial stiffness Aortic PWV was significantly higher in the carriers of the À1562C4T (TT homozygotes and CT heterozygotes) compared with the CC homozygote (Table 1) . There was a significant dose-dependent effect of the À1562C4T on aortic PWV (Figure 2) . In a stepwise multiple regression model, with PWV as the dependent variable and the known or likely confounders of arterial stiffness as independent variables, age and mean arterial pressure emerged as major determinants of aortic PWV in our cohort with a significant independent contribution from the À1562C4T polymorphism (Table 3) .
In contrast to PWV (Figure 2) , there was no significant difference in AIx between the three genotypes and the results were unchanged when AIx was adjusted for major confounders such as age, gender, mean arterial pressure, heart rate, height and smoking status.
MMP-9 À1562C4T polymorphism and plasma MMP-9 levels The average serum MMP-9 levels were higher in subjects carrying the T allele (TT homozygotes and CT heterozygotes) compared with the CC homozygotes ( Table 1 ). There was a significant dose-dependent effect of the À1562C4T polymorphism on serum levels of MMP-9 ( Figure 2 ). The MMP-9 genotype also significantly influenced serum MMP-9 levels after correcting for likely confounders including age, gender, BP and smoking status (R 2 ¼ 0.27, Po0.0001).
Discussion
This study shows that in never-treated hypertensive patients the MMP-9 À1562C4T promoter polymorphism is associated with higher BP and aortic stiffness with a significant gene-dose effect. Although PWV is strongly influenced by ageing and distending pressure, the À1562C4T polymorphism determined PWV independently of both age and BP. 
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Furthermore, the À1562C4T polymorphism was an independent predictor of both systolic and diastolic BP in these patients. In addition, the MMP-9 levels were also higher in the T-allele carriers with a significant gene-dose effect and the À1562C4T polymorphism was an independent determinant of serum MMP-9 levels. Aortic stiffness, measured as PWV, is an independent prognosticator of cardiovascular morbidity and mortality in both healthy 2 and hypertensive populations. [3] [4] [5] Circulating MMP-9 levels are increased in hypertension 10 and predict cardiovascular risk. 12 Genetic variation in the MMP-9 gene is associated with severity of vascular disease 12, 14 and with large artery stiffness. 15, 16 Medley et al. 15 showed increased aortic stiffness, measured as aortic input and characteristic impedance, pulse pressure and MMP-9 expression in T-allele carriers of the À1562C4T polymorphism in patients with CAD. However, while Yasmin et al. 16 reported increased PWV and MMP-9 levels in T-allele carriers they did not observe any significant difference in BP between the three genotypes in a normotensive population. In contrast, we have shown a significant gene-dose effect of the MMP-9 polymorphism not only on aortic PWV but also on BP. While Medley et al. 15 did not analyse their data to see if the presence of the polymorphism played an independent role in determining BP, our results extend to those of Yasmin et al. 16 by showing a significant difference in BP between the three genotypes in a hypertensive population. One can speculate why we were able to show such large BP differences. First, the contribution of the À1562C4T polymorphism to BP may only be significant in the presence of gene-environment interaction, which then results in hypertension in the genetically predisposed subjects and second, aortic stiffness may precede development of BP in those patients who carry the T allele. Whatever the mechanism, increased BP in T-allele carriers highlights the importance of studying these genetic polymorphisms in a hypertensive population. The finding of heart rate as an independent predictor of both systolic and diastolic BP was also interesting. Our study population comprised young patients with mild hypertension who normally exhibit a hyperkinetic circulation. Indeed, epidemiological data have shown that heart rate is associated with high BP, particularly in the early stages of hypertension.
18 Figure 1 The influence of MMP-9 polymorphism on brachial systolic (top) and diastolic (bottom) blood pressure in hypertensive patients (n ¼ 215, mean7s.d.). The À1562C4T allele has a dose-dependent effect on blood pressure (systolic P ¼ 0.005, diastolic P ¼ 0.05). MMP, matrix metalloproteinase. Abbreviation: BMI, body mass index.
Variables excluded in the model were smoking, total cholesterol, HDL and glucose (for (a)).
Variables excluded in the model were age, body mass index, smoking, total cholesterol, HDL and glucose (for (b)).
The high aortic stiffness and BP in the T-allele carriers may be secondary to excessive degradation of the arterial elastin matrix. The stiffness of the vascular wall is determined by the relative concentrations of collagen and elastin, which are kept tightly regulated by a balance between production and degradation in the extracellular matrix (ECM). When collagen production is accelerated at the expense of elastin, arteries become progressively stiffer. 19 We have shown previously a strong association between aortic stiffness and collagen turnover in hypertensive patients. 20 After the initial degradation by collagenases (MMP-1, MMP-8, MMP-13) and elastinase (MMP-7), further degradation of ECM basement membrane takes place by activation of MMP-9. 8 The MMP-9 À1562C4T polymorphism is a promoter polymorphism and the T-allele enhances the expression of the MMP-9 messenger RNA in cells. This may lead to increased synthesis of pro-MMP-9 and thus higher plasma MMP-9 levels. The presence of the T allele was associated with increased plasma MMP-9 levels and increased aortic stiffness in CAD and healthy subjects. 15, 16 The current study extends these findings to a hypertensive population where the T allele conferred increased BP and arterial stiffness, which were associated with higher plasma MMP-9 levels. Furthermore, there was a significant gene-dose effect, with heterozygotes exhibiting levels intermediate between those of CC and TT homozygotes. However, the increased MMP-9 levels associated with the T allele may promote arterial stiffness through vascular remodelling. Animal studies using MMP-9-deficient carotid artery cells have demonstrated that MMP-9 may influence vascular remodelling not only through matrix degradation but also through reorganization. 21 The increased aortic stiffness seen in the T-allele carriers may also result from vascular inflammation, which has been shown to stimulate collagen production in hypertension. 22 On the vessel wall, macrophage foam cells and vascular smooth muscle cells secrete MMP-9 in response to regulatory molecules, such as tumour necrosis factor-a, interleukin-1, platelet-derived growth factor and epidermal growth factor, 23, 24 which may contribute to increased BP and aortic stiffness. In hypertensive patients, high-sensitivity C-reactive protein, a marker of vascular inflammation is closely related with aortic stiffness. 17 While we observed a significantly higher PWV in T-allele carriers, the AIx was not significantly different between the three genotypes. AIx is a composite measure influenced by left ventricular contractility and intensity of reflected wave, which in turn depends on vascular smooth muscle tone in the muscular arteries and timing of the reflected wave, both of which are dependent on PWV. Therefore, alternations in the elastic aorta may occur Figure 2 The influence of MMP-9 polymorphism on aortic PWV (mean7s.d., top) and plasma MMP-9 levels (mean and 95% CI, bottom) in hypertensive patients (n ¼ 215). The À1562C4T allele has a dose-dependent effect on aortic PWV (P ¼ 0.004) and plasma MMP-9 concentration (P ¼ 0.01). CI, confidence interval; MMP, matrix metalloproteinase; PWV, pulse wave velocity. 26 The strengths of our study include a never-treated homogenous group of hypertensive patients, free from any cardiovascular disease or risk factors and equal numbers of both genders. Also, we used PWV that is the gold standard measure for aortic stiffness and is an independent prognosticator of cardiovascular events in a hypertensive population. [3] [4] [5] The study limitations include first a cross-sectional design, which does not allow us to infer causality between the genetic variants, MMP-9 levels and arterial stiffness. Second, measurement of plasma rather than tissue MMP-9 levels as the latter may me associated more closely with aortic stiffness. Serum MMP-9 levels have been shown to predict cardiovascular risk, 12 however, and direct measurement of plasma MMP-9 levels within the vascular wall during life is problematic for obvious reasons. Third, the frequency of the TT genotype was low and comprised largely of male subjects introducing some variability and gender bias in the study.
Hypertension is a major risk factor for stroke, heart disease and end-stage renal disease and is also one of the most complex gene-environment disorders, with genetic heritability averaging B28%. 27 The present study implicates the MMP-9 À1562C4T polymorphism as an independent player in modulating BP in a hypertensive population, possibly by increased arterial stiffness through matrix turnover in the vessel wall, although the effect is relatively small. Genotyping for MMP-9 À1562C4T polymorphism may identify patients who are at increased risk of cardiovascular disease and may guide antihypertensive therapy in the future. Long-term prospective studies in a hypertensive population, particularly employing agents that reduce PWV, are needed to see if these measures add to traditional cardiovascular risk assessment in hypertensive patients.
What is known on this topic K MMPs are a family of enzymes that play an important role in vascular remodelling K Plasma levels of MMP-9 predict cardiovascular mortality in coronary artery disease and are modulated variation in the MMP-9 gene K Plasma MMP-9 levels are increased in hypertension and associated with aortic stiffness in healthy subjects
What this study adds K 17% of the hypertensive population carried the rare T allele, which was associated with higher MMP-9 plasma levels K The MMP-9 1562 C4T polymorphism is associated with increased blood pressure and aortic stiffness but not with wave reflection in essential hypertension K The MMP-9 1562C4T polymorphism is an independent determinant of blood pressure and aortic stiffness in hypertensive patients MMP-9 gene and arterial stiffness in hypertension S Zhou et al
